Trump used the MFN model to break pharmaceutical companies
By Emilio Quesada · Reporting from Miami ·
The arithmetic of power is rarely polite, and it is never ideological when the savings are high enough.
The arithmetic of power yields to money. President Donald Trump’s announcement that every state, Puerto Rico, and the District of Columbia opted into his most favored nation drug-pricing model reflects a surrender to the dollar. As the New York Post reports, the administration pressured 26 major pharmaceutical companies to match rates paid in eight high-income nations, including Canada, Germany, and the UK.
For blue states that initially balked, the choice was stark: maintain performative opposition to the White House or secure steep discounts on essential medications for their poorest citizens. They chose the money. Leverage decides the outcome.
Governors Choose the Ledger
The model is a blunt instrument designed to end the era where the United States serves as the global pharmacy's ATM. According to ABC News, the White House estimates that these deals will save the federal government $529 billion over the next decade, with states saving an additional $64 billion for their Medicaid programs. For the 70 million Americans covered by state-administered Medicaid, this policy brings a lifeline.
| Jurisdiction | Projected Savings | Beneficiaries | | :--- | :--- | :--- | | Federal Government | $529 Billion (10-Year) | National Programs | | State Medicaid Programs | $64 Billion | 70 Million Americans |
Health and Human Services Secretary Robert F. Kennedy Jr. and Medicare and Medicaid administrator Dr. Mehmet Oz frame this as a moral imperative. Dr. Oz noted that the $50 billion states currently pay after rebates crowds out schools and roads. Reclaiming that capital hands state governors a budget windfall just in time for the November midterms.
Critics like Kathy Hempstead of the Robert Wood Johnson Foundation argue that the lack of transparency in these deals makes it unreasonable for Congress to codify them. This reaction displays the typical credulity of the policy class. Years drafting sanctions at Treasury taught that the clarity of a deal remains secondary to enforcement. Pharmaceutical companies dropped prices because the U.S. government leveraged the only thing they fear: the loss of the American market.
Precedent in the Code
Federal power operates through fundamental American mechanisms. The logic matches the Interstate Commerce Act of 1946. That law prohibited the predatory price discrimination that allowed monopolies to squeeze farmers in the West and South while favoring the Eastern establishment. The Act recognized that when a service is essential and the provider is a monopoly, the government must mandate reasonable and just pricing to prevent corporate exploitation.
The pharmaceutical industry operated for decades as a legal monopoly, charging Americans a premium that subsidizes the healthcare systems of allies. By instituting the MFN policy via executive order, Trump treats prescription drugs like essential infrastructure that cannot engage in price discrimination against domestic taxpayers.
Softer approaches failed before. The Patient Protection and Affordable Care Act (2010) attempted to overhaul access through complex subsidies and mandates, but it lacked the raw leverage to break the pricing power of Big Pharma. Similarly, the 2010 healthcare reform efforts sought systemic changes bogged down in the bureaucracy protecting the status quo. Even the American Recovery and Reinvestment Act of 2009 showed that coordinated state and federal action can stabilize a crisis, but it functioned as a stimulus, not a structural correction. This MFN model dictates the price rather than managing the cost.
Surrendering the Boardroom
The administration moves to codify these arrangements, triggering lawsuits from the pharmaceutical lobby. Drug makers will argue that the executive order represents an overreach. They are wrong. The U.S. government purchases more drugs than any entity in the world; suggesting it cannot negotiate the price of its own purchases remains a fantasy.
The launch of TrumpRx for the uninsured signals that the administration intends to expand this leverage beyond Medicaid rolls. If the administration maintains this pressure, the meaningful progress cited by JD Hayworth of the Pharmaceutical Reform Alliance will become a permanent shift in the power dynamic between Washington and the boardroom.
American power acts as a load-bearing wall. Decisive use turns the unreasonable into the inevitable. Pharmaceutical companies capitulated to the dollar because the alternative brought irrelevance. States joined because the math outweighed the politics.